About Associate Professor Rachael Morton

Rachael Morton specialises in novel, trial-based and modelled economic evaluation, and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.

Rachael Morton is an Associate Professor of Health Economics at the Sydney Medical School, and Director of Health Economics at the NHMRC Clinical Trials Centre which is internationally recognised for its knowledge and experience in clinical trials. The CTC is dedicated to attracting and nurturing high-calibre PhD candidates who contribute significantly to the development of the centre’s research, which currently supports 13 candidates. Read their testimonies, here: http://www.ctc.usyd.edu.au/education/higher-research-degrees.aspx. Associate Professor Morton has lead the methodological development of discrete choice experiments for elicitation of patient and partner preferences in chronic disease and the economic evaluation of surgical interventions in melanoma. Together with her colleagues, she has published a cost-effectiveness analysis in melanoma using a Markov decision analytic model that has been used as accompanying evidence to support an application for reimbursement under the Medicare Benefits Schedule. A second cost-effectiveness analysis for induction immunosuppression in kidney transplantation was adopted by the international Kidney Disease Improving Global Outcomes (KDIGO) guidelines for transplantation. Associate Professor Morton has substantial clinical trials experience and served for 9 years as executive member of the Australia and New Zealand Melanoma Group (ANZMTG) and as health economics advisor to the Royal Australia and New Zealand College of Radiologists (Faculty of Radiation Oncology). She is a current member of the Australia and New Zealand Society of Nephrology (ANZSN) Dialysis Advisory Committee, and a member of the university’s Science in Australia Gender Equity (SAGE) self-assessment team.

Associate Professor Morton has supervised 2 PhD students to completion - 1 was nominated for the Peter Bancroft prize for no emendations. Currently, she co-supervises 5 PhD candidates at the University of Sydney / UNSW; 1 MD student and 2 Masters students. In addition she provides technical guidance to the Medical Services Advisory Committee review team at the NHMRC Clinical Trials Centre and is a mentor to 2 junior health economists.

Associate Professor Morton is a member of the Cancer Institute NSW steering committee on ‘Costs of cancer trials'; a Grant Review Panel member for Cancer Australia; international evaluator for the UK NICE/ NIHR Health Technology Assessments; and health economics editor for Nephrol Dial Transpl journal. She has been a Guest Discussant for the Economic Sub Committee of the Pharmaceutical Benefits Advisory Committee (PBAC) for the Australian Government.

Associate Professor Morton has attracted the following prizes, awards and honours:
• NHMRC Sidney Sax ECR Public Health Fellowship
• Honorary Investigator, Melanoma Institute Australia
• Helen Triantyfallou Conference award, (Top ranked applicant) Sydney Medical School, 2015
• Dean's commendation Sydney Medical School, for best student research paper 2010
• Best research paper and Best oral presentation - Renal Society of Australasia 2009Service:
• In 2014/15 A/Prof Morton was part of the successful Athena SWAN Silver Award application for the Nuffield Department of Population Health in Oxford
• In 2016 she became a member of the University of Sydney's Science in Australia Gender Equity (SAGE) self assessment team

Selected publications

For a full list of Associate Professor Morton's Publicatons please see her academic profile here.

Top 10 publications in the past 5 years' demonstrate her leadership in health economics research:

1. Watts CG, Cust AE, Mann G, Menzies S, Morton RL. The cost-effectiveness of skin surveillance through a specialised clinic for patients at high risk of melanoma. Accepted J Clin Oncol.(2016)

2. Webster AC, Nagler E, Morton RL, Masson P. Lancet seminar: Chronic Kidney Disease. Accepted The Lancet. (2016)

3. Merom D, Mathieu E, Cerin E, Morton RL, Simpson J, Rissel C, Anstey KJ, Sherrington C, Lord SR, Cumming RG. Social dancing to reduce the incidence of falls in older adults - a cluster randomized controlled trial. Accepted PLoS Medicine.(2016)

4. Morton RL, Kurella-Tamura M, Coast J, Davison S. Supportive Care: Economic Considerations in Advanced Kidney Disease. Clin J Am Soc Nephrol. (2016). doi: 10.2215/CJN.12651115

5. Watts CG, ... Morton RL. Specialized surveillance for individuals at high risk of melanoma: a cost analysis of a High Risk Clinic. JAMA Dermatology (2014)

6. Dieng M, Cust AE, Kasparian NA, Mann GJ, Morton RL. Economic evaluations of psychosocial interventions in cancer: A systematic review. Psycho-Oncology. (2015) doi: 10.1002/pon.4075. http://www.ncbi.nlm.nih.gov/pubmed/26810383

7. Morton RL. Essential inputs for studies of cost-effectiveness analysis in melanoma. Editorial. British Journal of Dermatology. 171(6):1294 (2014). DOI: 10.1111/bjd.13455.

8. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease. PLoS Medicine (2012). 9(9): e1001307. doi:10.1371/journal.pmed.1001307.

9. Morton RL, Snelling P, Webster AC, Rose JM, Masterson R, Johnson DW, Howard K. Factors influencing patient choice of dialysis versus conservative care for treatment of end-stage kidney disease. CMAJ. (2012) 20;184(5):E277-83. doi: 10.1503/cmaj.111355. http://www.ncbi.nlm.nih.gov/pubmed/22311947.

10. Davison SN, Levin A, Moss A, Jha V, Brown E, Brennan F, Murtagh F, Naicker S, Germain M, O'Donoghue D, Morton RL, Obrador G. Executive Summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: Developing a Roadmap to Improving Quality Care. Kidney International (Nature series). (2015) DOI: 10.1038/ki.2015.110